Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 20, 2025
Daily News
February 20, 2025
- Create NDA Category Modeled after FDA’s “505(b)(2)” Pathway: JEMA
February 20, 2025
- Ex-Lawmakers Launch Council for Revamping Japan’s Drug Innovation
February 20, 2025
- Chuikyo OKs Pricing Rules for FY2025 Drug Price Revision
February 20, 2025
- CDP Submits Bill Calling for Outright Freeze on Copay Cap Reform
February 20, 2025
- Kaken Set to Take Stab at US Market with Vascular Malformation Drug
February 20, 2025
- Pfizer Japan to Discontinue Amoxapine after Carcinogen Issue
February 20, 2025
- Sakigake Tag Withdrawn for 2 Boehringer Drugs
February 20, 2025
- Pfizer Pulls Japan NDA for Hemophilia Gene Therapy Beqvez as Program Called Off Globally
February 20, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…